Rubella virus infection is transmitted by respiratory droplets and causes a generally mild disease characterized by a rash and fever, primarily in children. However, infection in women during early pregnancy may cause fetal death or congenital rubella syndrome (CRS) in the infant [1] . CRS is a significant cause of deafness, blindness, congenital heart disease, and mental retardation [2] ; although precise burden of disease is unknown, it is estimated that 110,000 CRS cases occur each year in developing countries [1, 3] .
Rubella is vaccine-preventable; the primary objective of rubella-control programs is prevention of congenital rubella virus infection, which includes CRS. Rubella is among the small number of viral diseases considered to be potentially eradicable [4, 5] . Rubella can be eliminated in countries that have introduced routine rubella vaccination for children and achieved high coverage in the population. In September 2010, achievement of the goal of rubella and CRS elimination in the region of the Americas was announced by the Pan American Health Organization [6, 7, 8] . However, countries that introduce rubella vaccine and achieve suboptimal vaccination coverage may be at risk for a paradoxical increase in susceptibility among older age groups, potentially leading to acquisition of rubella virus infections among women of childbearing age and to an increase in CRS cases [9] [10] [11] . To decrease the risk of rubella virus infections among pregnant women and consequent CRS cases, the World Health Organization (WHO) recommends introduction of rubella vaccine should be considered only in countries that have achieved high (.80%) coverage with the first-dose measles-containing vaccine [1] .
WHO recommends that countries without rubella vaccination programs should assess the burden of rubella and CRS [2] . Integrated case-based surveillance with laboratory testing to detect measles and rubella is recommended in countries with an established measles elimination or rubella control goal [12] . In Africa, several countries have conducted subnational rubella seroprevalence surveys; however, none has established routine surveillance for CRS.
Since 1999, as part of the WHO and United Nations Children's Fund (UNICEF) measles mortality reduction strategy in Africa, case-based surveillance with laboratory testing for all suspected measles cases has been established. By December 2008, 40 of 46 countries in the African Region of WHO-all except Algeria, Comoros, Guinea Bissau, Mauritius, Sao Tome and Principe, and Seychelles-established measles and rubella case-based surveillance [13] following the WHO African Regional Office (AFRO) measles-surveillance guidelines [14] . Laboratory testing for rubella IgM antibody is recommended for specimens found to be negative or indeterminate for measles IgM antibody [14] .
Given that little is known about rubella in Africa, we provide an overview of published seroprevalence surveys and analysis of surveillance and laboratory data as a baseline of prevaccine-era rubella epidemiology in NOTE. a Studies that reported rubulla sero-positivity results for an age group older than 12 years of age or described as 'women of reproductive age'
b Reproductive age was undefined in the study.
c For estimates where the original manuscript did not report a confidence interval, we calculated a Wald confidence interval (in italics) for a binomial proportion assuming the observations within a given study are independent.
d Laboratory Tests: HAI, haemagglutination inhibition; SRH, single radial haemolysis; HI, haemagglutination inhibition; EIA, enzyme immunoassay; RH, radial.haemolysis; ELISA, enzyme-linked immunosorbent assay.
Africa, in preparation for the introduction and widespread use of rubella vaccine throughout the region.
METHODS

Literature Review
To identify previously published rubella seroprevalence surveys in Africa, we conducted a Medline search using the National Library of Medicine's PubMed online search engine. Keywords included 'rubella' combined with 'Africa'. The starting year was not defined, the end date was June 2010, and no language priority was chosen. A 'related article' hyperlink was followed for each retrieved article. The reference list of the retrieved articles was used to identify related literature. We included a study in the summary table if the article reported seroprevalence results and contained a description of study design, study population, and age group(s) tested. If the original article did not report a confidence interval for prevalence, we calculated a Wald confidence interval for a binomial proportion.
Surveillance Data Analysis
We analyzed regional measles case-based surveillance data collected and reported by 40 African countries during 2002-2009. We included data from each country in the analysis, starting in the year following completion of the nationwide catch-up measles supplementary immunization activity and continuing through all subsequent years. The data were collected following the WHO guidelines [14] using a standard case definition for a suspected measles case, which is illness with a generalized maculopapular rash and fever, and at least 1 of the following: cough, coryza (runny nose), or conjunctivitis [14] . For each case, surveillance officers collected detailed information including case-patient data on age, sex, address, and number of doses of measles vaccine received. Blood specimens were collected from persons with suspected measles cases identified within 30 days of rash onset and tested for measles-specific immunoglobulin M (IgM) antibody using standard enzyme-linked immunosorbent assay [15] . If results were negative or indeterminate for measles IgM, sera were subsequently tested for presence of rubella-specific IgM antibody using standard enzyme-linked immunosorbent assay. Laboratory testing was performed at an accredited national measles laboratory with support from WHO AFRO [14] .
We included any country with $30 laboratory-confirmed rubella cases reported during 2002-2009 in our analysis of age, sex, and location of cases by country. We divided the countries included in the analysis into 4 sub-Saharan African subregions based on geography: West (Benin, Burkina Faso, Cô te d'Ivoire, Gambia, Ghana, Guinea, Liberia, Mali, Mauritania, Nigeria, Niger, Senegal, Sierra Leone, and Togo), Central (Angola, Cameroon, Central African Republic, Chad, Congo, Democratic Republic of the Congo, Equatorial Guinea, and Gabon), East (Burundi, Eritrea, Ethiopia, Kenya, Rwanda, Tanzania, and Uganda), and South (Botswana, Lesotho, Madagascar, Malawi, Mozambique, Namibia, South Africa, Swaziland, Zambia, and Zimbabwe). To graphically explore the temporal trends of confirmed rubella cases in each geographical subregion, we overlay a smoothed curve over a histogram of cases counts for each month from year 2002 to 2009. We used cumulative percent curves to graphically describe the age distribution of laboratory-confirmed rubella cases. We categorized age into 5 groups (,1 y, 1-4 y, 5-9 y, 10-14 y, and $15 y), and for analysis of the surveillance data, reproductive age was defined as 15-49 years. We log-transformed age data and used a 2-sample t test to compare the means of rural versus urban settings. The test accounted for the potential cluster effect of country with standard errors estimated via the Taylor-series method. We analyzed data using SAS version 9.2 and R version 2.11.0 (Free Software Foundation, GNU project).
Vaccination Coverage Review
National administrative vaccination coverage is reported annually by each country, using the WHO and UNICEF Joint Reporting Form [16] . WHO and UNICEF, in collaboration with each national Ministry of Health, generate vaccination coverage estimates based on the reported national administrative coverage, available surveys, and results from independent coverage verification [17] .
RESULTS
Literature Review
The search of published literature found 22 reports of rubella seroprevalence surveys during 1963-2009 from 14 (30%) of the 46 countries in the African region. Rubella seropositivity ranged from 68%-98%, and varied by age group (Table 1) . Of the 22 studies, 17 reported seropositivity results for group aged .12 years or described as ''women of reproductive age''. Of these 17 studies, the rubella seropositivity ranged from 71%-99%, and varied by study group and age group (Table 1) . In 3 studies of rubella seropositivity among women of reproductive age with a study population .1000, rubella seropositivity was found to be 94. measles cases were reported; of these, 105,625 had a specimen sent for laboratory testing to detect rubella-specific IgM antibody (Table 2) . Among those tested, 25,631 cases (24%) were confirmed as rubella, 70,218 (66%) had negative test results, 4677 (4%) had indeterminate test results, and 5099 (5%) were unknown with pending results (Table 2) .
Of the 25,631 confirmed rubella cases-patients, 25,097 (98%) had information on age; 3% were aged ,1 year, 28% were aged 1-4 years, 47% were aged 5-9 years, 16% were aged 10-14 years, and 5% were 15 years of age or older ( Table 3 ). The mean age of persons with rubella virus infection was 7.3 years (interquartile range [IQR] 5 4.2-9.0 y) (Figure 1) . Overall, 12,271 (50%) of confirmed rubella cases were among females, and 1293 (5%) were among women of reproductive age (15-49 y). Information on household location (rural vs urban) was available for 16,782 (65%) case-patients; of these, 10,527 (63%) were from rural settings and 6255 (37%) from urban settings (Table 3) . Information on age and household location was available for 16,627 (65%) confirmed cases; in urban settings, mean age was 6.8 years (IQR 5 3.9-8.5 y) and in rural settings, mean age was 7.5 years (IQR 5 4.2-9.8 y) (P 5 .004).
Yearly seasonality of reported laboratory-confirmed rubella cases by month of rash onset varied among the 4 subregions (Figure 2 ). In the West subregion, during 2003-2009, marked seasonality of rubella occurred each year with sharp increases in reporting during January with peaks in March-April followed by sharp declines in May, leading to troughs during OctoberDecember each year. In the Central subregion, data were sparse; however, peaks generally occurred during February-March and troughs were observed during September-November. In the East subregion, reporting varied by year; however, biphasic reporting was generally observed with peaks in March-April and in September-October and annual troughs in DecemberJanuary and May-June. In the South subregion, a distinct annual seasonality was observed with consistently few cases reported during January-June each year, followed by gradual increases in June-July and peaks in September-October.
Vaccination Coverage Review
Of the 46 countries in the WHO African Region, 17 (37%) had estimated first-dose measles-containing vaccine coverage .80% in 2009 (Table 3) . Of these, 2 (12%), Mauritius and Seychelles, have introduced rubella vaccine into the national routine childhood immunization schedule [18] .
DISCUSSION
Rubella virus is circulating widely in Africa and primarily infects young children. The surveillance data suggest that by 15 years of age most children have developed immunity from natural infection. However, 5% of reported rubella cases occurred in women of reproductive age, suggesting that rubella infection during pregnancy, which can potentially lead to CRS, occurs throughout the region and remains largely undetected. Underreporting of milder rubella cases among adults is a potential reporting bias because the measles-rubella surveillance system is primarily focused on detection and reporting of suspected measles cases that generally occur among children. Point prevalence estimates from serological surveys throughout Africa estimated susceptibility to rubella virus among adults ranged from 1%-29% among the various study populations, whereas the 3 largest studies in Africa of women of reproductive age found that 6%-16% were susceptible to rubella virus infection. This is the first report to review rubella epidemiology in the African region. Our findings are similar to those observed Equatorial Guinea 2006-2009  1  1 100  1 100  0  0  0  0  0  0  0  0  0  0  1 100  1  100  51   Eritrea  2004-2009  154  85  55  62  44  78  56  3  2  37 24  72 47  32 21  10  6  10  6  95   Ethiopia  2004-2009  1,035  558  54  504  49  528  51  37  4  352 34  457 44  134 13  54  5  54  5  75   Gabon  2005-2009  99  49  49  22  23  72  77  1  1  20 20  47 47  24 24  7  7  7  7  55   Gambia  2004-2009  59  34  60  28  54  24  46  2  3  22 37  23 39  10 17  2  3  2  3  96   Ghana  2002-2009  966  490  51  427  45  524  55  30  3  360 37  349 36  127 13  95  10  94  10  93   Guinea  2004-2009  38  26  68  5  13  33  87  0  0  9 24  25 66  3  8  1  3  1  3  51 Guinea-Bissau
during the prevaccine era in other regions [3, 19, 20] . In Europe and the Americas, the age distribution of cases was similar to that in Africa, and rubella was primarily a childhood disease that occurred mainly among 5-to 9-year-olds [21] . In some countries in Africa, the proportion of cases was highest among children ,5 years of age, suggesting the possibility of infection at a younger age; however, the numbers of cases were small and limitations of the surveillance data should be considered. In the United States, prior to the use of rubella vaccine, 80% of reported rubella cases occurred by 14 years of age and 92% by 20 years of age; however, seroprevalence studies estimated susceptibility to rubella among persons 17-22 years of age was 15%-20% [22] . Susceptibility to rubella among persons in rural settings was lower than in urban settings during the prevaccine era in Europe, the Americas, and Asia; and is consistent with our finding of an older mean age of reported cases in rural settings than in urban settings in Africa [21, 23] . The significantly younger mean age of reported cases in urban settings compared with that of rural settings in Africa may be due to rubella infection occurring at younger age in areas with high population density and contact rates. In the United States, annual seasonality of rubella was observed, with an increase in cases occurring in the early winter, peaking in March and decreasing to a low point in late summer and autumn; in general, annual seasonal peaks in rubella cases occur during springtime in temperate climates [21, 24] . We found similar seasonality in the South subregion of Africa, which includes countries located in the southern temperate zone. CRS data from Africa are limited to descriptive reports of individual cases from Kenya, Uganda, and Senegal and caseseries studies of clinically diagnosed CRS from Tanzania, Nigeria, Zimbabwe, and Ghana [3, 25, 26] . Of these small studies, 3 reported $18 clinically diagnosed CRS cases. In Ghana, 18 infants with clinically diagnosed CRS born within a 5-month period were identified following a large epidemic that included 40,276 suspected measles cases reported in 1995; however, no cases of rubella were reported [25, 27] . Assuming that the outbreak was caused by rubella instead of measles, the estimated congenital rubella syndrome rate was .8 cases per 1000 live births [25] . A case-series study from Harare, Zimbabwe, reported 18 clinically-diagnosed CRS cases following simultaneous epidemics of rubella and measles associated with an influx of refugees in the 1970s [28] . In Nigeria, a retrospective medical record review from 2000-2007 in a tertiary hospital identified 19 clinically diagnosed CRS cases [26] .
These findings should be considered with knowledge of several limitations. Rubella cases were detected through a surveillance system designed to detect measles, and the clinical presentation of rubella may not meet the suspected measles case definition; 20%-50% of rubella infections do not include a rash and documented by several seroprevalence studies. Prevention of rubella through vaccination is largely unavailable in Africa despite the .80% routine measles vaccination coverage achieved by more than one-third of countries in the region [18] . As of October 2010, only 2 countries in the region have introduced rubella vaccine into their national immunization program.
A main concern when considering introducing rubella vaccination is that low vaccination coverage (typically described as ,80%) may decrease virus circulation sufficiently to shift both the average age of exposure to rubella and rubella susceptibility from children to older age groups including women of childbearing age, and therefore may increase the prevalence of CRS. Such a shift in susceptibility to older age groups occurred and was documented in Greece and South Africa [10, 29] . As childhood rubella immunization programs mature, even with high coverage the percentage of remaining rubella cases shifts toward older age groups. However, the rubella susceptibility rate in older age groups, the absolute rubella risk, and the potential risk of CRS do not increase and may actually decrease. Several mathematical models have predicted that a certain minimum vaccination-coverage level may be important in determining the optimal strategy for the introduction of rubella vaccine; however, depending on the parameters used in these models, the minimum vaccination-coverage level can vary from 70%-85%.
In conclusion, we have documented that rubella virus circulates widely in Africa. Evidence of the CRS burden is limited to date; in 1996, it was estimated that 22,500 infants with CRS are born annually in the WHO African Region [30] . To fully understand the burden of rubella and CRS and to determine the most appropriate strategies for rubella control and CRS prevention, a comprehensive approach is needed. Following WHO recommendations, rubella surveillance should be integrated with measles case-based surveillance, CRS surveillance should be established, the routine immunization program should be strengthened, and the introduction of rubella vaccination should be carefully considered to ensure rubella immunity among women of reproductive age. 
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